Made-in-China New Drugs: The Game and Breakthrough in the Over - 4 - Billion Market
Profiles 16 China-made blockbuster drugs exceeding ¥1B sales, highlighting intense PD-1 competition, EGFR tech innovation, and bispecific antibody/non-oncology surge.
September 5, 2025
by Lezhi
Made-in-China New Drugs: Breaking Through the RMB 4-Billion Battlefield
In 2024, the "Billion-Yuan Club" of made-in-China first-in-class new drugs expanded to 16 members.
September 5, 2025
by lezhi
No Increase in Risk With Dapagliflozin in Patients With Stage 4 CKD
For patients with stage 4 chronic kidney disease (CKD), a similar pattern of reduced kidney, cardiovascular, and mortality risks is seen with dapagliflozin versus placebo, with no evidence of increased risks.
July 22, 2021
by drugs
Vela Diagnostics Announces Collaboration with the National Cancer Centre of Singapore to Refine Novel Cancer Therapy
Vela Diagnostics announced a collaboration with the National Cancer Centre of Singapore (NCCS) to develop a molecular diagnostic assay to predict individual patients' responses to a cancer therapy called Epidermal Growth Factor Receptor (EGFR) ...
June 4, 2021
by prnasia
Rybrevant Approved for NSCLC With EGFR Exon 20 Insertion Mutations
Rybrevant (amivantamab-vmjw) was approved for adults with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, the U.S. Food and Drug Administration announced Friday.
May 26, 2021
by drugs
Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS).
May 26, 2021
by firstwordpharma
FDA approves Janssen’s Rybrevant
The US Food and Drug Administration (FDA) has approved Janssen’s Rybrevant as the first treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
May 25, 2021
by pharmatimes
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S
Bridge Biotherapeutics Inc., a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity of BBT-176 in ...
April 7, 2021
by prnasia
Janssen Submits BLA for Metastatic Lung Cancer Treatment
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic ...
December 24, 2020
by americanpharmaceuticalreview
NICE backing for AZ' Tagrisso
AstraZeneca's Tagrisso (osimertinib) has been recommended for use within NHS England, in line with its licensed indication, for adults with untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR) ...
September 15, 2020
by pharmatimes
Tagrisso shows 'unprecedented' disease free survival in lung cancer
According to AstraZeneca, its EGFR inhibitor Tagrisso (osimertinib) has shown 'unprecedented disease-free survival' in the adjuvant treatment of patients with EGFR-mutated lung cancer.
June 1, 2020
by pharmatimes
Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer
AstraZeneca announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for adults with locally-advanced...
September 5, 2019
by worldpharmanews